PLK1 and malignant peripheral nerve sheath tumor: Follow-up profiling of PLK1 inhibitors found them to be effective across six NF1-related MPNST lines (ST88-14, T265, ST88-3, 90.8, and S462TY) and one sporadic MPNST (STS-26T, now recognized as a melanoma line).